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For a long time, it was commonly believed that efficient anticancer regimens would either trigger 
the apoptotic demise of tumor cells or induce a permanent arrest in the G1 phase of the cell cycle, 
i.e., senescence. The recent discovery that necrosis can occur in a regulated fashion and the 
increasingly more precise characterization of the underlying molecular mechanisms have raised 
great interest, as non-apoptotic pathways might be instrumental to circumvent the resistance 
of cancer cells to conventional, pro-apoptotic therapeutic regimens. Moreover, it has been 
shown that some anticancer regimens engage lethal signaling cascades that can ignite multiple 
oncosuppressive mechanisms, including apoptosis, necrosis, and senescence. Among these 
signaling pathways is mitotic catastrophe, whose role as a bona fide cell death mechanism has 
recently been reconsidered.  Thus, anticancer regimens get ever more sophisticated, and often 
distinct strategies are combined to maximize efficacy and minimize side effects. In this review, 
we will discuss the importance of apoptosis, necrosis, and mitotic catastrophe in the response 
of tumor cells to the most common clinically employed and experimental anticancer agents.
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and necrosis, respectively, whereas the existence of bona fide 
“autophagic cell death” remains a matter of controversy, as in 
most instances the inhibition of autophagy accelerates, rather 
than inhibits, cell death (Kroemer and Levine, 2008).
Following the discovery of the signaling pathways that initiate 
the cellular demise, of the biochemical mechanisms that execute it, 
and of its consequences at the organismal level, several additional 
criteria have been used to classify cell death. For instance, at a bio-
chemical level, cell death sometimes, but not always, requires the 
activation of a specific class of cysteine proteases, namely caspases, 
leading  to  the  discrimination  between  caspase-dependent  and 
caspase-independent cell death. From an immunological stand-
point, immunogenic cell death (ICD) has been opposed to cell 
death that is unable to activate the immune system (silent), or even 
actively represses it (tolerogenic). Finally, functional aspects have 
been used to discriminate between accidental and programmed 
cell death (PCD), or between physiological and pathological cell 
death (Galluzzi et al., 2007).
Along with an ever more precise mechanistic characterization 
of the cellular demise, in the last decade several neologisms have 
been coined to indicate presumably novel cell death subroutines 
that exhibit peculiar morphological, biochemical or functional 
features (Kroemer et al., 2009). The terms “anoikis,” “parapto-
sis,” “pyroptosis,” and “pyronecrosis” are a few examples that 
exemplify this tendency. However, in most cases, these catabolic 
pathways do not constitute bona fide cell death mechanisms, but 
rather signaling cascades that engage the apoptotic or necrotic 
IntroductIon
For a long time, cell death was considered as a mere “conse-
quence”  of  cellular  life  and  neglected.  Then,  starting  in  the 
mid-nineteenth century, the demise of cells begun to attract the 
attention of some biologists, who compiled the first morpho-
logical descriptions of cell death. Nevertheless, the notion that 
cell death can occur in a programmed fashion was not explicitly 
formulated until as late as 1964, thanks to the seminal work of 
Richard Lockshin (Lockshin and Williams, 1964). A few years 
later, John Kerr, Alastair Currie, and Sir Andrew Wyllie, who 
were studying ischemic injury in the rat liver, described for the 
first time a form of mammalian cell death that manifests with 
peculiar morphological features and named it “apoptosis,” a term 
of Greek derivation that translates the “dropping off” of petals 
or leaves from plants or trees (Kerr, 1965; Kerr et al., 1972). 
As suggested by its stereotyped nature, apoptosis constitutes a 
genetically regulated cell death subroutine, a concept that was 
consolidated in 1980–1990 thanks to the work of Robert Horvitz 
in Caenorhabditis elegans (Lettre and Hengartner, 2006). Along 
with the discovery of apoptosis, attempts were made to classify 
cell death modes based on morphological features. One of such 
classifications was proposed by Schweichel and Merker in 1973, 
who exposed rat embryos to toxicants and observed “type I cell 
death” associated with heterophagy, “type II cell death” associated 
with autophagy and “type III cell death,” which was not associated 
with any type of digestion (Schweichel and Merker, 1973). Today, 
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the intracellular activation of initiator caspase-8 and execu-
tioner caspase-3 and -6 (Wajant, 2002). On the other hand, 
“intrinsic apoptosis” responds to a wide array of intracellular 
stress conditions (e.g., DNA damage, oxidative damage) and is 
controlled by mitochondria, whose permeabilization constitutes 
a point-of-no-return in the signaling pathway that leads to the 
activation of the caspase-9-caspase-3 cascade as well as of mul-
tiple caspase-independent cell death effectors (e.g., apoptosis-
inducing factor, AIF; endonuclease G) (Kroemer et al., 2007). 
Thus, several biochemical markers have been associated with 
the execution of apoptotic cell death including: (i) the massive 
activation of caspases, in particular caspase-3, -6, -8, and -9; (ii) 
mitochondrial membrane permeabilization and (iii) the inter-
nucleosomal cleavage of DNA (Kroemer et al., 2007; Table 1).
However, none of the morphological features and processes 
that have been linked to apoptosis can be used alone as a bona 
fide indicator of this cell death subroutine (Kroemer et al., 2009), 
for several reasons. First, taken singularly, some of these mor-
phological traits can manifest (and most of these biochemical 
events can occur) during non-apoptotic instances of cell death 
(Vandenabeele et al., 2010). For instance, MMP reportedly takes 
place during apoptosis and programmed necrosis (Kroemer et al., 
2007; Vandenabeele et al., 2010). Second, not all of these (mor-
phological and functional) characteristics manifest in all instances 
of apoptosis. As a major example, apoptosis can occur independ-
ently of caspases (Chipuk and Green, 2005). Third, it has recently 
become evident that most, if not all, the players that mediate PCD 
also have cell death-unrelated functions (Galluzzi et al., 2008). 
Thus, the activation of the apoptotic executioner caspase-3 and 
MMP have been implicated in the differentiation of hematopoi-
etic cells (Zermati et al., 2001; De Botton et al., 2002). Similarly, 
the caspase-independent cell death effector AIF, which mediates 
large scale DNA degradation once released from mitochondria 
(Joza et al., 2001; Kroemer et al., 2007), regulates the assembly/
stability of the respiratory complex I from its physiological locali-
zation, i.e., within the mitochondrial intermembrane space (Joza 
et al., 2005).
Apoptotic cells produce several well-known “find-me” (e.g., 
soluble lysophosphatidylcholine, LPC; ATP) (Lauber et al., 2003; 
Elliott et al., 2009) and “eat-me” (e.g., surface-exposed and oxidized 
phosphatidylserine) (Martin et al., 1995) signals, which allow them 
to interact with macrophages and to be recruited into tight-fitting 
phagosomes through a zipper-like mechanism (Krysko et al., 2006). 
Often, phagocytic cells that take up apoptotic bodies do not activate 
inflammatory or immunogenic reactions. Thus, for a long time it 
was thought that developmental and pathological PCD would occur 
only via apoptosis, as this would not elicit any kind of immune 
response, in contrast to the well-known inflammatory potential 
of necrosis (see below) (Galluzzi et al., 2007; Green et al., 2009). 
This oversimplified view has been definitively invalidated in 2007, 
when Obeid et al. (2007) demonstrated that some anticancer agents 
such as anthracyclins and γ irradiation are able to kill cancer cells by 
apoptosis while rendering them able to stimulate a tumor-specific 
immune response. Since then, great efforts have been directed to the 
discovery of the molecular mechanisms underlying ICD and it has 
turned out that ICD depends on the activation of a multi-module 
machinery (Kepp et al., 2010). Similarly, it seems that “mitotic 
catastrophe,” which in the past has been defined as a cell death 
instance   occurring during or shortly after an aberrant mitosis 
(Vakifahmetoglu et al., 2008), cannot be considered as a cell 
death subroutine on its own but rather as an oncosuppressive 
mechanism that can trigger apoptosis, necrosis, or senescence. 
Importantly, whereas necrosis has been regarded for a long time 
as a purely accidental cell death mode, it has recently been shown 
that it can also occur in a regulated fashion (Vandenabeele et 
al., 2010).
Before  this  revolutionary  change  of  perspective  occurred, 
it was believed that efficient anticancer regimens would either 
kill tumor cells by engaging the apoptotic machinery or per-
manently arrest them in the G1 phase of the cell cycle, thus 
inducing senescence. Now, it has become evident that there is a 
wide array of clinically employed and experimental anticancer 
agents that function by triggering neither “classical” apoptosis 
nor senescence. Some of these regimens, which are beyond the 
scope of this review, work by engaging tumor-extrinsic signaling 
cascades (e.g., they stimulate an antitumor immune response, 
they inhibit angiogenesis, etc.). Others may induce programmed 
necrosis or mitotic catastrophe-engaged apoptosis. These notions 
have generated considerable interest. On one hand, regimens that 
kill tumor cells by inducing necrosis might be instrumental to 
circumvent the elevated incidence among tumors of mechanisms 
for the evasion of apoptotic cell death. On the other hand, it 
seems that cancer cells (which are often genomically instable) 
are much more sensitive to the induction of mitotic catastrophe 
than their normal counterparts, resulting in a more comfortable 
therapeutic window (Eom et al., 2005).
In this review, we will summarize the main morphological, bio-
chemical, and immunological features of apoptosis, necrosis and 
mitotic catastrophe and we will discuss the significance of these 
lethal biochemical cascades in anticancer therapy.
caspase-dependent and -Independent apoptosIs
The morphological features that define the most-studied modal-
ity of cell death, apoptosis, include (i) rounding-up of the cell; 
(ii) retraction of pseudopodes; (iii) reduction of cellular volume; 
(pyknosis), (iv) chromatin condensation starting from the nuclear 
periphery (marginalization), followed by overall nuclear shrink-
age and breakdown (karyorrhexis); (v) little or no ultrastructural 
modifications of cytoplasmic organelles; (vi) plasma membrane 
blebbing (but maintenance of its integrity until the latest stages 
of the process); (vii) shedding of vacuoles containing cytoplasmic 
portions and apparently unchanged organelles (known as apop-
totic bodies); and (viii) engulfment of apoptotic bodies by resident 
phagocytes (in vivo) (Galluzzi et al., 2007). When the phagocytic 
system is absent (e.g., in cell cultures) or inefficient, apoptotic 
bodies progressively break down and their content spills into the 
extracellular milieu (secondary necrosis).
According to accepted models, two distinct routes to apop-
tosis exist, which are ignited by extracellular and intracellular 
stress signals, respectively. “Extrinsic apoptosis” is predomi-
nantly mediated by so-called death receptors (e.g., CD95/FAS), 
which deliver a lethal signal upon ligand binding, resulting in www.frontiersin.org  May 2011  | Volume 1  | Article 5  |  3
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Table 1 | Main morphological, biochemical, and inflammatory/immunological features of apoptosis, necrosis, and mitotic catastrophe.
  Morphological features  Biochemical features  Inflammatory/immune features
Apoptosis  Rounding-up  Caspase activation  Generation of soluble find-me signals (ATP , LPC)
  Pseudopode retraction  MMP/LMP  Uptake via tight-fitting phagosomes
  Cytoplasmic pyknosis  ∆ψm dissipation  Often anti-inflammatory and silent/tolerogenic
  Chromatin condensation  Release of IMS proteins  In some instances, eliciting an immune 
  Karyorrhexis  PS exposure  response that depends on CRT exposure
  Little alterations of organelles  Internucleosomal DNA cleavage 
  PM blebbing  ROS overgeneration 
  Apoptotic bodies  ATP depletion 
  Phagocytosis  Activation of calpains/cathepsins 
Necrosis  Increasingly translucent  RIP1/RIP3 activation  Uptake by macrophages      
  cytoplasm  Increased glutamino- and glycogenolysis  via micropinocytosis
  Swollen organelles  ROS overgeneration  Most often, pro-inflammatory
  Dilatation of the nuclear  Sphingosine and ceramide  In some cases, anti-inflammatory
  membrane  overproduction
  Chromatin condensation  MMP/LMP 
  in small irregular patches  Cytosolic Ca2+ waves
  Absent karyorrhexis  Activation of calpains/cathepsins 
  Oncosis  cPLA2 activation 
  PM breakdown  PARP1 hyperactivation 
    ANT inhibition 
    ATP and NAD +  depletion 
    Impaired LIP homeostasis  
    Sometimes, PS exposure 
Mitotic catastrophe  Micronucleation  Activation of caspase-2  Poorly determined
  Multinucleation  Prolonged SAC signaling  Most likely, dependent on the executioner
  Apoptotic and/or necrotic  TP53 activation  mechanism engaged (i.e., apoptosis,
  features  Aberrant levels of cyclin B1 and  necrosis or senescence)
    signaling via CDK1 
Abbreviations: ANT, adenine nucleotide translocase; CDK1, cyclin-dependent kinase 1; cPLA2, cytosolic phospholipase A2; CRT, calreticulin; ∆ψm, mitochondrial 
transmembrane potential; IMS, mitochondrial intermembrane space; LIP , labile iron pool; LMP , lysosomal membrane permeabilization; LPC, lysophosphatidylcholine 
MMP , mitochondrial membrane permeabilization; PARP1, poly(ADP-ribose) polymerase 1; PM, plasma membrane; RIP , receptor-interacting protein kinase; ROS, 
reactive oxygen species; SAC, spindle-assembly checkpoint.
signaling pathway that eventually results in the exposure at the cell 
surface of the endoplasmic reticulum (ER) chaperones calreticu-
lin (CRT) and ERp57 (Panaretakis et al., 2009). The ecto-CRT/
ERp57 complex acts as an “eat-me” signal and functions by bind-
ing to a yet-to-be-identified receptor on the surface of dendritic 
cells (DCs), stimulating the uptake of tumor antigens by DCs and 
the DC-mediated cross-priming of tumor-specific T lymphocytes 
(Obeid et al., 2007; Panaretakis et al., 2009).
Numerous  clinically  used  and  experimental  anticancer 
agents trigger apoptosis (Table 2). These range from DNA-
damaging agents including cisplatin (Schwerdt et al., 2005), 
ionizing radiations (Mi et al., 2009), and mitomycin c (Pirnia et 
al., 2002) to proteasome inhibitors such as bortezomib (Bonvini 
et al., 2007; Shi et al., 2008), from corticosteroids like pred-
nisone (Casale et al., 2003) to inhibitors of histone deacety-
lases (HDACs) such as vorinostat (Koyama et al., 2010), from 
topoisomerase I inhibitors like camptothecin (Sanchez-Alcazar 
et al., 2003), etoposide (Cosse et al., 2007), and mitoxantrone 
(Cao et al., 2009) to a large number of monoclonal antibodies 
including bevacizumab (Wedam et al., 2006), cetuximab (Niu 
et al., 2010), and trastuzumab (Hudis, 2007), just to mention 
a few examples.
programmed necrosIs
Similar to their apoptotic counterparts, necrotic cells exhibit pecu-
liar morphological features, though these have been disregarded for 
decades, along with the conception of necrosis as a totally uncon-
trollable and accidental phenomenon (Table 1). Initially, necrotic 
cells were classified in a negative fashion, i.e., dying cells that neither 
showed morphological traits of apoptotic nor massive autophagic 
vacuolization (which was considered a sign of autophagic cell 
death). Now, it has become evident that cells succumbing to necro-
sis display (i) an increasingly translucent cytoplasm; (ii) swollen 
organelles; (iii) little ultrastructural modifications of the nucleus 
including the dilatation of the nuclear membrane and the con-
densation of chromatin into circumscribed, asymmetrical patches; 
and (iv) increased cell volume (oncosis), which culminates in the 
breakdown of the plasma membrane (Vandenabeele et al., 2010). Frontiers in Oncology  | Molecular and Cellular Oncology    May 2011  | Volume 1  | Article 5  |  4
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Table 2 | Examples of anticancer agents that operate via apoptosis.
Class  Agent Main indication(s) Reference
ClInICAlly EMPlOyEd 
Angiogenesis inhibitors Thalidomide Multiple myeloma Mitsiades et al. (2002), Gockel et al. (2004)
Anthracyclins Daunorubicin AML
ALL











Wang et al. (2004), Casares et al. (2005), Ji et al. (2010)





Ketley et al. (1997), Majsterek et al. (2005)
Antimetabolites 6-Mercaptopurine Leukemia
NHL
da Silva et al. (1996), Hortelano and Bosca (1997)
Capecitabine Breast cancer (metastatic)
Colorectal cancer










Vrana et al. (1999), Nishioka et al. (2007)





Hwang et al. (2001), Rigas et al. (2002)
Methotrexate ALL da Silva et al. (1996), Huang et al. (2011)
Pralatrexate (Folotyn®)  Leukemia
PTCL
Marneros et al. (2009), Marchi et al. (2010)




Thiantanawat et al. (2003), Howell (2005)
Thiantanawat et al. (2003), Lisztwan et al. (2008)
Chimeric antibodies Rituximab (Rituxan®) B-cell NHL 
CLL
Cartron et al. (2004), Marignani et al. (2009)
Corticosteroids Prednisone ALL 
CLL 
HL 




Lanza et al. (1996), (Casale et al., 2003)
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DNA-damaging agents Carboplatin NSCLC
Ovarian cancer
Girnun et al. (2008), Vidot et al. (2010)















Kandioler-Eckersberger et al. (2000), Schiavoni et al. (2011)







Watters (1999), Mi et al. (2009)





Park et al. (2000), Kelly et al. (2000), Pirnia et al. (2002)
Oxaliplatin Colorectal cancer Gourdier et al. (2004), Tesniere et al. (2010)
Glucocorticoids Dexamethasone  Brain cancer
Multiple myeloma 
Brown et al. (1993), Sharma and Lichtenstein (2008)
HDAC inhibitors Vorinostat (Zolinza®)  Cutaneous T-cell lymphoma Fantin and Richon (2007), Koyama et al. (2010)
Immunomodulatory agents Lenalidomide (Revlimid®) Multiple myeloma Wu et al. (2008), Chauhan et al. (2010)
Macrolides Rapamycin (Syrolimus®) Multiple hematopoietic and 
solid tumors
Castedo et al. (2002), Huang et al. (2004)





















Nuckel et al. (2005), Jaglowski et al. (2010)
Wedam et al. (2006)
Van Cutsem et al. (2009), Niu et al. (2010)
Cheson (2010)
Hoy and Wagstaff (2006), Van Cutsem et al. (2007), Dubois 
and Cohen (2009)
Shan et al. (2001), Cardarelli et al. (2002)
Mohsin et al. (2005), Hudis (2007)
mTOR inhibitors Everolimus (Afinitor®) ALL
Subependymal giant cell 
astrocytoma 
Renal cell carcinoma
Beuvink et al. (2005), Motzer et al. (2008), Crazzolara et al. 
(2009)
Temsirolimus (Torisel®)  Renal cell carcinoma Hudes et al. (2007), Mahalingam et al. (2010)
Class  Agent Main indication(s) Reference
Table 2 | Continued
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Class  Agent Main indication(s) Reference
Table 2 | Continued
Proteasome inhibitors  Bortezomib (Velcade®)  Mantle cell lymphoma 
Multiple myeloma
Bonvini et al. (2007), Shi et al. (2008)
Retinoids Alitretinoin (Panretin®)  Kaposi’s sarcoma Fujimura et al. (1998), Dezube (2000)
Bexarotene (Targretin®)  Cutaneous T-cell lymphoma Budgin et al. (2005), Wagner et al. (2009)
Tretinoin (Vesanoid®)  APL Warrell et al. (1991), Sakoe et al. (2010)
Selective estrogen receptor 
modulators
Fulvestrant (Faslodex®) Breast cancer Bundred and Howell (2002), Riggins et al. (2005)
Raloxifene (Evista®) Breast cancer Obrero et al. (2002), Mori-Abe et al. (2003)
Tamoxifen (Nolvadex®) Breast cancer Nazarewicz et al. (2007), Howell et al. (2005)
Topoisomerase I inhibitors Camptothecin Lung cancer 
Lymphoma 
Ovarian cancer
Traganos et al. (1996), Sanchez-Alcazar et al. (2003)
Irinotecan Colorectal cancer Xu and Villalona-Calero (2002), Li et al. (2009)
Topotecan Cervical cancer 
Ovarian cancer 
SCLC
Caserini et al. (1997), Nakashio et al. (2000)










Bhalla et al. (1993), Cao et al. (2009)
Tyrosine kinase inhibitors Dasatinib (Sprycel®)  ALL 
CML
Prostate cancer
Talpaz et al. (2006), Guerrouahen et al. (2010)
Erlotinib (Tarceva®)  NSCLC 
Pancreatic cancer
Ling et al. (2008), Felip et al. (2008)
Gefitinib (Iressa®)  NSCLC Tracy et al. (2004), Mok et al. (2009)





Vigneri and Wang (2001), Schiffer (2007)
Lapatinib (Tykerb®) Breast cancer Geyer et al. (2006), Olaussen et al. (2009)
Pazopanib (Votrient®)  Renal cell carcinoma Olaussen et al. (2009), Paesler et al. (2010)
Sorafenib (Nexavar®)  GIST
Hepatocellular carcinoma 
Renal cell carcinoma 
(metastatic)
Escudier et al. (2007), Llobet et al. (2010)
Sunitinib malate (Sutent®) GIST
Renal cell carcinoma
Gore et al. (2009), Xin et al. (2009)
In ClInICAl dEvElOPMEnT
Alkylating agents Mafosfamide CNS cancer (Phase 1)
Meningeal neoplasms 
(Phase 1)
Pette et al. (1995), Goldstein et al. (2008)
Corticosteroids Predinisolone ALL (Phase 4) da Silva et al. (1996), Boor et al. (2006)
Flavonoids Alvocidib (Flavopiridol) CLL (Phase 1–3)
Rhabdoid tumors 
(Phase 1–3)
Byrd et al. (1998), Billard et al. (2003)
(Continued)www.frontiersin.org  May 2011  | Volume 1  | Article 5  |  7
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consequent release of toxic hydrolases into the cytosol (Boya and 
Kroemer, 2008); (v) the generation of cytosolic Ca2+ waves, driv-
ing the activation on one hand of Ca2+-dependent non-caspase 
proteases of the calpain family that favor LMP (Yamashima et 
al., 2003; Yamashima, 2004; Yamashima and Oikawa, 2009), and, 
on the other hand, of the cytosolic phospholipase A2 (cPLA2), 
which catalyzes the first step in the conversion of phospholipids 
into membranotoxic lipid peroxides (Jayadev et al., 1997; Shinzawa 
and Tsujimoto, 2003); (vi) the hyperactivation (possibly induced 
by ROS-triggered DNA damage) of the ATP- and NAD+-dependent 
nuclear enzyme poly(ADP-ribose) polymerase 1 (PARP1), favoring 
ATP and NAD+ depletion as well as the mitochondrial release of 
AIF via a calpain-mediated mechanism (Yu et al., 2002; Zong et al., 
2004; Moubarak et al., 2007); (vii) the inhibition of the ATP/ADP 
exchanger of the inner mitochondrial membrane adenine nucle-
otide translocase (ANT), contributing to ATP depletion (Temkin 
et al., 2006); and (viii) the generation of a c-JUN N-terminal kinase 
(JNK)-transduced signal affecting the homeostasis of the redox-
active labile iron pool (LIP), further promoting oxidative stress 
(Antosiewicz et al., 2007). Most likely this list is not exhaustive and 
additional processes that are involved in the necrotic disintegration 
of cells will be discovered in the forthcoming years.
Similar to their apoptotic counterparts, necrotic cells sometimes 
externalize phosphatidylserine before plasma membrane permea-
bilization (Krysko et al., 2004), promoting their recognition and 
uptake by phagocytes (Hirt and Leist, 2003; Brouckaert et al., 
Necrosis does not result in the formation of discrete entities that 
would be similar to apoptotic bodies. Moreover, the nuclei of 
necrotic cells do not fragment similar to those of their apoptotic 
counterparts and have indeed been reported to accumulate in 
necrotic tissues, in vivo. It should be kept in mind that whereas 
the signaling pathways and biochemical mechanisms the underlie 
programmed, accidental, and secondary necrosis are distinct, these 
phenomena manifest with highly overlapping end-stage morpho-
logical features. It is therefore impossible to discriminate among 
these three processes by relying on single end-point morphological 
determinations (Galluzzi et al., 2009).
The biochemical processes that ignite and execute programmed 
necrosis have only recently begun to be unveiled. These include, 
but are not limited to: (i) the activation of receptor-interacting 
protein kinases 1 and 3 (RIP1 and RIP3, respectively), which have 
recently been shown to play a critical role in several instances or 
programmed necrosis, and in particular in tumor necrosis factor 
receptor 1 (TNFR1)-elicited necroptosis (Hitomi et al., 2008; Cho 
et al., 2009; He et al., 2009; Zhang et al., 2009); (ii) a metabolic 
burst involving the glycogenolytic and glutamynolytic cascades 
(Goossens et al., 1996; Zhang et al., 2009); (iii) the overgeneration 
of reactive oxygen species (ROS) by mitochondrial and extra-mito-
chondrial sources (Goossens et al., 1995, 1999; Kim et al., 2007); 
(iv) the overproduction of membrane-destabilizing lipids such as 
sphingosine and ceramide (Thon et al., 2005; Won and Singh, 2006), 
promoting lysosomal membrane permeabilization (LMP) and the 
Class  Agent Main indication(s) Reference
Table 2 | Continued




Wu et al. (2008), Chauhan et al. (2010)
Macrolides Rapamycin (Syrolimus) Multiple hematopoietic and 
solid tumors (Phase 1–3)
Castedo et al. (2002), Huang et al. (2004)
Monoclonal antibodies Dacetuzumab (SGN-40®) Multiple myeloma (Phase 2) Law et al. (2005)1
Epratuzumab ALL (Phase 1–3)
NHL (Phase 1–3)
Stein et al. (2004), Carnahan et al. (2007)
GA101 B-cell lymphoma (Phase 1)
NHL (Phase 1)
Dalle et al. (2011)1
Galiximab B-cell lymphoma (Phase 3) Bello and Sotomayor (2007)
Ofatumumab (Arzerra®) B-cell CLL (Phase 3)
Follicular NHL (Phase 3)
Cheson (2010)1
Veltuzumab NHL (Phase 2) Stein et al. (2004), Rossi et al. (2008)
mTOR inhibitors Everolimus (Afinitor®) Large B-cell lymphoma 
(Phase 3)
Beuvink et al. (2005), Motzer et al. (2008), Crazzolara et al. 
(2009)
Proteasome inhibitors Bortezomib (Velcade®)  Large B-cell lymphoma 
(Phase 3)
Bonvini et al. (2007), Shi et al. (2008)
Topoisomerase I inhibitors Camptothecin Multiple solid tumors 
(Phase 1–3)
Traganos et al. (1996), Sanchez-Alcazar et al. (2003)
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic 
myeloid leukemia; CNS, central nervous system; GIST, gastrointestinal stromal tumor; HDAC, histone deacetylase; HL, Hodgkin’s lymphoma; HNSCC, head and neck 
squamous cell carcinoma; MDS, myelodysplastic syndrome; mTOR, mammalian target of rapamycin; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer; 
PTCL, peripheral T-cell lymphoma; SCLC, small cell lung cancer.
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(Vitale et al., 2011). Second, multiple chemotherapeutic agents 
that are now employed at relatively high doses to trigger cell cycle-
independent cell death are very efficient at inducing mitotic catas-
trophe at lower doses (Eom et al., 2005).
The most prominent morphological features of mitotic catastro-
phe are (i) micronucleation and (ii) multinucleation. Micronuclei 
often derive from chromosomes and/or chromosome fragments 
that have not been distributed evenly between daughter nuclei, 
whereas two or more nuclei with similar or heterogeneous sizes 
can be generated upon an aberrant karyokinesis (Vakifahmetoglu 
et al., 2008). Once mitotic catastrophe proceeds and engages apop-
tosis, necrosis, or cell senescence, cells acquire at least some of the 
morphological traits that characterize these processes, resulting in 
a spectrum of morphotypes that are difficult to classify.
The biochemical events that accompany mitotic catastrophe 
have not yet been precisely characterized, and there seems to be a 
high degree of variability in the molecular cascades that are acti-
vated in distinct instances of mitotic catastrophe (Gascoigne and 
Taylor, 2008). Thus, most of the processes that so far have been 
linked to mitotic catastrophe are required for this lethal cascade in 
some, but not all, experimental settings. These include (i) the acti-
vation of the DNA damage-responsive caspase-2, which reportedly 
can operate both upstream and downstream MMP (Krumschnabel 
et  al.,  2009;  Vakifahmetoglu-Norberg  and  Zhivotovsky,  2010); 
(ii) the protracted activation of the spindle-assembly checkpoint 
(SAC), which prevents anaphase (and hence chromosome misseg-
regation) in cells with spindle defects or misattached chromosomes 
(Musacchio and Salmon, 2007); (iii) the activity of the tumor sup-
pressor protein TP53 (Castedo et al., 2006; Vitale et al., 2007; Huang 
et al., 2009); and (iv) aberrantly high levels of cyclin B1, leading 
to prolonged activation of the cyclin-dependent kinase 1 (CDK1) 
(Harley et al., 2010; Terrano et al., 2010).
Although a role for pro- and anti-apoptotic proteins from the 
BCL-2 family, for TP53 and for several SAC-related and -unrelated 
kinases has been demonstrated (Puthalakath et al., 1999, 2001; 
Castedo et al., 2006; Musacchio and Salmon, 2007; Harley et al., 
2010; Terrano et al., 2010), it remains to be clarified how mitotic 
catastrophe signals to the molecular machineries of apoptosis, necro-
sis or senescence, and which factors determine the choice among 
these three oncosuppressive mechanisms. A detailed analysis of the 
crosstalk between mitotic catastrophe and the inflammatory and 
immune systems is also missing. With regards to this, it is tempting 
to speculate that the reaction of the inflammatory/immune system 
to cells undergoing mitotic catastrophe might be deeply influenced 
(if not entirely dictated) by the cell fate, be it apoptosis, necrosis, or 
senescence. Future work will confirm or invalidate this hypothesis. 
Irrespective  of  these  incognita,  an  entire  class  of  clinically 
employed anticancer agents, i.e., microtubular poisons, operate 
by inducing mitotic catastrophe. These include taxanes, which dis-
rupt microtubular functions by stabilizing polymerized tubulin; 
vinca alkaloids, which acts as tubulin depolymerizers; as well as 
recently developed compounds such as epothilones, which mimic 
the activity of taxanes yet bind to a distinct binding site on tubu-
lin (Dumontet and Jordan, 2010). In addition, there are several 
inducers of mitotic catastrophe that are currently being evaluated 
in pre-clinical and clinical settings, including inhibitors of Aurora 
kinases (Perez Fidalgo et al., 2009; Lens et al., 2010), of checkpoint 
2004). However, full-blown necrosis results in the recruitment of 
macrophages that internalize necrotic cells via spacious macropi-
nosomes (Krysko et al., 2003), a phenomenon that involves the 
sorting of fluid-phase macromolecules, as demonstrated by the 
co-localization of fluid-phase tracers (Krysko et al., 2006). Thus, 
apoptotic and necrotic cells are handled by the immune system 
in a radically different fashion. Nevertheless, the phlogistic and 
immunological consequences of these cell death subroutines can-
not be summarized by the old belief that apoptosis always inhibits, 
while necrosis always stimulates, inflammation and immunity. On 
one hand, immunogenic instances of apoptosis have been reported 
(see above). On the other hand, in some cases, necrotic cells can 
suppress inflammatory reactions (Hirt and Leist, 2003; Brouckaert 
et al., 2004). These observations suggest that the complexity of the 
mutual crosstalk between dying cells and the immune system has 
not been clearly understood yet.
Some clinically employed anticancer regimens (e.g., photody-
namic therapy) have been associated with the necrotic regression 
of tumors (Bown et al., 2002; Lou et al., 2004; Moore et al., 2009), 
but in most cases it remains to be determined whether such a 
therapeutic response truly reflects the induction of programmed 
necrosis. Nevertheless, along with the increasingly more refined 
understanding of the molecular cascades that underlie regulated 
necrosis, several compounds are being investigated at pre-clinical 
and clinical levels for their ability to kill cancer cells by inducing 
necrosis. Notable examples include DNA alkylating agents, which 
may trigger cancer cell necrosis via PARP1 hyperactivation (Zong 
et al., 2004); inhibitors of the cellular inhibitor of apoptosis (cIAP) 
protein family such as SMAC mimetics, which (at least in vitro) 
promote necroptosis by facilitating the deubiquitination of RIP1 
(Dineen et al., 2010; Vandenabeele et al., 2010; Vanlangenakker et al., 
2011); and shikonin, whose promising pro-necrotic activity has not 
yet been precisely characterized (Han et al., 2007) (Table 3).
mItotIc catastrophe
In the last decade, the term “mitotic catastrophe” has been exten-
sively employed to describe a form of cell death affecting higher 
eukaryotes and has been defined in several fashions, for instance as 
a case of cell death occurring either during or shortly after aberrant 
mitosis (Vakifahmetoglu et al., 2008). Nevertheless, the current 
literature is devoid of a clear-cut definition of this process. The 
present tendency is to consider mitotic catastrophe as an onco-
suppressive signaling cascade that precedes the cellular demise (or 
senescence) rather than a bona fide cell death executioner mecha-
nism (Vakifahmetoglu et al., 2008; Vitale et al., 2011). Thus, based 
on functional considerations, mitotic catastrophe can be viewed as 
a signaling pathway that is activated by perturbations of the mitotic 
apparatus (including chromosomes and the machinery that ensure 
their faithful segregation) that are sensed during mitosis and that 
lead first to (at least some extent of) mitotic arrest and then to cell 
death of senescence.
In spite of (or even along with) this change of perspective, the 
interest in mitotic catastrophe as a target for anticancer regimens 
continues to be high, for at least two reasons. First, a sizeable pro-
portion of cancer cells are tetraploid or aneuploid, which renders 
them intrinsically more prone to mitotic aberrations and hence 
particularly  sensitive  to  the  induction  of  mitotic  catastrophe www.frontiersin.org  May 2011  | Volume 1  | Article 5  |  9
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Table 3 | Examples of anticancer agents that ignite programmed necrosis or mitotic catastrophe.
Class  Agent Main indication(s) Reference
ClInICAlly EMPlOyEd 




Kandioler-Eckersberger et al. (2000), Zong et al. (2004)
Epothilones Ixabepilone Breast cancer Lee and Swain (2008)
Estrogens Estramustine Prostate cancer Panda et al. (1997), Dumontet and Jordan (2010)
HDAC inhibitors Romidepsin (Istodax®) Cutaneous T cell lymphoma Peart et al. (2003), Woo et al. (2009), Whittaker et al. 
(2010)
Photodynamic therapy Temoporfin HNSCC
Pancreatic cancer
Prostate cancer
Bown et al. (2002), Lou et al. (2004), Moore et al. (2009)
Taxanes Cabazitaxel HRPC (metastatic) Galsky et al. (2010)












Nyman et al. (2005), Perez (2009), Miele et al. (2009), 
Dumontet and Jordan (2010)
Vinca alkaloids Vinblastine (Velban®) Multiple hematopoietic and solid 
tumors
Dumontet and Jordan (2010)
Vincristine (Oncovin®) Multiple hematopoietic and solid 
tumors




Dancey and Steward (1995), Joel (1996)
Vinflunine Bladder cancer Frampton and Moen (2010)
Vinorelbine Breast cancer
NSCLC
Aapro et al. (2007), Gralla et al. (2007)
In PREClInICAl/ClInICAl dEvElOPMEnT
AURKs inhibitors AS703569 Multiple hematopoietic and solid 
tumors (Phase 1)
McLaughlin et al. (2009)1
AT9283 Leukemia (Phase 1–2)
Multiple myeloma (Phase 2)
Cheung et al. (2009)1
AZD1152 AML (Phase 1–3)
Solid tumors (advanced) (Phase 1)
Wilkinson et al. (2007)1
MK-0457 (VX-680) Leukemia (Phase 2)
NSCLC (Phase 2)
Solid tumors (advanced) (Phase 1)
Harrington et al. (2004), Dar et al. (2010)
MLN8054 Solid tumors (advanced) (Phase 1) Hoar et al. (2007), Kitzen et al. (2010)
MLN8237 AML (advanced) (Phase 2)
MDS (Phase 2)
Solid tumors (advanced) (Phase 1)
Kitzen et al. (2010), Huck et al. (2010)
PF-03814735 Solid tumors (advanced)  (Phase 1) Kitzen et al. (2010), Jani et al. (2010)
PHA-739358 CML (Phase 2)
Multiple myeloma (Phase 2)
HRPC (metastatic) (Phase 2)
Carpinelli et al. (2007)1
SNS-314 Solid tumors (advanced) (Phase 1) Cheung et al. (2009), VanderPorten et al. (2009)
cIAPs inhibitors SMAC/DIABLO mimetics Preclinical development Foster et al. (2009), He et al. (2009), Awasthi et al. (2011)
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Table 3 | Continued
Class  Agent Main indication(s) Reference
CENP-E inhibitors GSK923295 Solid tumors (Phase 1) Wood et al. (2010)
CHEK1 inhibitors AZD7762 Solid tumors (advanced) (Phase 1) Zabludoff et al. (2008), Dai and Grant (2010)
PF-00477736 Solid tumors (advanced) (Phase 1) Blasina et al. (2008), Ma et al. (2011)
SCH900776 Acute leukemia (Phase 1)
Lymphoma (Phase 1)
Solid tumors (Phase 1)
Dai and Grant (2010)1
UCN-01 Multiple hematopoietic and solid 
tumors (Phase 1–2)
Busby et al. (2000), Ma et al. (2011)1
Combretastatins CA4P (Fosbretabulin®) Anaplastic thyroid cancer (Phase 3)
HNSCC (Phase 2)
Solid tumors (Phase 1)






Solid tumors (Phase 1–3)
Solid tumors (Phase 1–3)
Solid tumors (Phase 1–3)
Perez (2009)1
Rivera et al. (2008), De Geest et al. (2010)
O’Reilly et al. (2008), Perez (2009)
Hoffmann et al. (2008), Galmarini (2009)
HDAC inhibitors Romidepsin (Istodax®) Multiple myeloma (Phase 2) Niesvizky et al. (2011)1
KRP inhibitors ARRY-520 AML (Phase 1–2)
Multiple myeloma (Phase 1–2)
Solid tumors (Phase 1)
Huszar et al. (2009), Woessner et al. (2009)
AZD4877 AML (Phase 1)
Bladder cancer (Phase 2)
Solid tumors (Phase 1)
Huszar et al. (2009)1
LY2523355 Acute leukemia (Phase 2)
Solid tumors (Phase 1)
Huszar et al. (2009)1
SB-715992 (Ispinesib®) Breast cancer (Phase 2)
Colorectal cancer (Phase 2)
Hepatic cancer (Phase 2)
HNSCC (Phase 2)
NSCLC (Phase 2)
Ovarian cancer (Phase 2)
Prostate cancer (Phase 2)
Renal cell carcinoma (Phase 2)
Lad et al. (2008), Sarli and Giannis (2008)1
Huszar et al. (2009)1
SB-743921 NHL (Phase 1–2)
Solid tumors (Phase 1)
Macrocyclic ketons Eribulin mesylate 
(Haraven®)
Breast cancer (Phase 3)
NSCLC (Phase 2)
Solid tumors (advanced) (Phase 1)
Twelves et al. (2010), Gradishar (2011)
Natural compounds Shikonin Preclinical development Han et al. (2007), Hu and Xuan (2008)
Noscapinoids Noscapine Multiple myeloma (Phase 1–2)
NHL (Phase 1–2)
Ye et al. (1998)1
PLK1 inhibitors BI 2536 AML (Phase 2)
NSCLC (Phase 2)
Pancreatic cancer (Phase 2)
Prostate cancer (Phase 2)
SCLC (Phase 2)
Steegmaier et al. (2007), Degenhardt and Lampkin 
(2010), Lens et al. (2010)
BI 6727 AML (Phase 2)
NSCLC (Phase 2)
Solid tumors (Phase 1)
Rudolph et al. (2009), Lens et al. (2010)1
GSK431634A NHL (Phase 1) Gilmartin et al. (2009), Degenhardt and Lampkin (2010)
ON01910.Na AML (Phase 1–2)
MDS (Phase 3)
Ovarian cancer (Phase 2)
Solid tumors (Phase 1)
Gumireddy et al. (2005)1
(Continued)www.frontiersin.org  May 2011  | Volume 1  | Article 5  |  11
Galluzzi et al.  Pathways to cancer cell death
Table 3 | Continued
Class  Agent Main indication(s) Reference
Survivin inhibitors LY2181308 AML (Phase 2)
HRPC (Phase 2)
NSCLC (Phase 2)
Carrasco et al. (2011)1
Peptide vaccine Breast cancer (Phase 1)
Cervical cancer (Phase 1–2)
Colorectal cancer (Phase 1–2)
Melanoma (Phase 1–2)
Pancreatic cancer (Phase 1–2)
Ryan et al. (2009)1
Terameprocol Leukemia (Phase 1)
Solid tumors (Phase 1)
Smolewski (2008), Ryan et al. (2009)
YM155 HRPC (Phase 2)
Large B cell lymphoma (Phase 2)
Melanoma (Phase 2)
NSCLC (Phase 2)
Nakahara et al. (2011)1
Taxanes Docetaxel Various solid tumors (Phase 3) Dumontet and Jordan (2010)1
Larotaxel Pancreatic cancer (Phase 3) Metzger-Filho et al. (2009)1
Milataxel (MAC321) Mesothelioma (Phase 2)
Solid tumors (Phase 1)
Sampath et al. (2003)1
Paclitaxel Various solid tumors (Phase 3) Dumontet and Jordan (2010)1
Topoisomerase I inhibitors β-lapachone HNSCC (Phase 2) Solid tumors 
(Phase 1)











Hewitt et al. (2010)
Kwiatkowski et al. (2010)
Colombo et al. (2010)
Santaguida et al. (2010)
Schmidt et al. (2005)




Various solid tumors (Phase 1–3)
Various solid tumors (Phase 1–3)
Various solid tumors (Phase 1–3)
Various solid tumors (Phase 1–3)
Dumontet and Jordan (2010)1
Dumontet and Jordan (2010)1
Dumontet and Jordan (2010)1
Dumontet and Jordan (2010)1
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; AURKs, Aurora kinases; CA4P , combretastatin 
A-4 phosphate; CENP-E, centromere protein E; CHEK1, checkpoint kinase 1; cIAPs, cellular inhibitor of apoptosis proteins; CML, chronic myeloid leukemia; DIABLO, 
direct IAP-binding protein with low pI; HNSCC, head and neck squamous cell carcinoma; HRPC, hormone-refractory prostate cancer; KRPs, kinesin-related proteins; 
MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer; PLK1, Polo-like kinase 1; SCLC, small cell lung cancer; SMAC, 
second mitochondria-derived activator of caspases.
1http://www.clinicaltrials.gov
kinase 1 (CHEK1) (Dai and Grant, 2010; Ma et al., 2011), of Polo-
like kinases (PLKs) (Degenhardt and Lampkin, 2010; Lens et al., 
2010), of survivin (Ryan et al., 2009), and of kinesin-related pro-
teins (Huszar et al., 2009), just to mention a few examples (Table 3).
concludIng remarks
So far, two major biochemical cascades that execute cell death 
have been characterized, i.e., apoptosis and necrosis. While the 
cytocidal potential of autophagy remains rather controversial, 
mitotic catastrophe appears to be an oncosuppressive mechanism 
that operates upstream of the molecular machinery for cell death 
and cell senescence. As we have discussed above, the vast majority 
of clinically used and experimental anticancer regimens work 
by triggering the apoptotic demise of tumor cells, programmed 
necrosis and mitotic catastrophe being much less employed as 
therapeutic targets. Nevertheless, since most, if not all, cancer 
cells exhibit or acquire increased resistance against pro-apop-
totic agents, the future of anticancer therapy also relies on the 
exploitation of non- and pre-apoptotic signaling cascades. The 
concept of programmed necrosis has gained consensus only a 
few years ago, along with the idea of circumventing apoptosis 
resistance by triggering necrosis. Mitotic catastrophe can result 
in the activation of three distinct oncosuppressive mechanisms, 
i.e., apoptosis, necrosis and senescence, and cancer cells appear 
to be intrinsically more sensitive to succumb to this type of death 
than their normal counterparts. Thus, programmed necrosis and 
mitotic catastrophe hold great promises for anticancer therapy. 
It will be really interesting to see how the recent knowledge that 
has been generated around these oncosuppressive mechanisms 
will be translated into a clinical reality.Frontiers in Oncology  | Molecular and Cellular Oncology    May 2011  | Volume 1  | Article 5  |  12
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